Literature DB >> 17576330

Histologic mimickers of mycosis fungoides: a review.

Kavitha Reddy1, Jag Bhawan.   

Abstract

Mycosis fungoides (MF) is a rare type of non-Hodgkin's lymphoma affecting the skin. Because MF develops slowly over several years and may have a variety of clinical presentations, including itchy patches, plaques or tumors that may be confused with common benign conditions such as eczema and psoriasis, the disease presents a diagnostic challenge. The average time to diagnosis varies but is frequently as long as 3 to 6 years. Skin biopsies frequently reveal non-specific features of several dermatoses; thus, histologic evaluation of the disease is also challenging. Importantly, various significant and/or benign conditions may mimic MF histologically and result in a misdiagnosis of MF. Here we review the reported histologic mimickers of MF and discuss both similar and differentiating features of each, in order to aid in more accurate interpretation of diagnostically challenging skin biopsies. Clinicopathologic correlation is ultimately essential to make accurate diagnosis of MF and its histologic mimickers.

Entities:  

Mesh:

Year:  2007        PMID: 17576330     DOI: 10.1111/j.1600-0560.2006.00662.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  10 in total

1.  An uncommon diagnosis for a recurrent erythematous patch in a paediatric patient.

Authors:  Priya Umesh Patel
Journal:  BMJ Case Rep       Date:  2017-12-07

2.  Hodgkin's lymphoma in a patient on adalimumab treatment for psoriasis.

Authors:  Nouf Alballa; Alanoud Alyousef; Albatool Alamari; Ahmed Abdullah Alhumidi; Mohammed Ayesh Zayed; Leena Zeitouni; Fahad Mohammed Alsaif
Journal:  AME Case Rep       Date:  2018-12-24

Review 3.  Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update.

Authors:  Thamy Yamashita; Luciana Patricia Fernandes Abbade; Mariangela Esther Alencar Marques; Silvio Alencar Marques
Journal:  An Bras Dermatol       Date:  2012 Nov-Dec       Impact factor: 1.896

4.  Fulminant Mycosis Fungoides with Tissue Eosinophilia: A Unique Presentation of Two Cases with Acro-Periorbital Ulceration and An Aggressive Clinical Course.

Authors:  David R Pearson; Mayumi Fujita; Whitney A High
Journal:  J Mol Biomark Diagn       Date:  2017-03-02

5.  Cutaneous T-cell lymphoma in erythrodermic cases may be suspected on the basis of scalp examination with dermoscopy.

Authors:  Adriana Rakowska; Magdalena Jasińska; Mariusz Sikora; Joanna Czuwara; Patrycja Gajda-Mróz; Olga Warszawik-Hendzel; Małgorzata Kwiatkowska; Anna Waśkiel-Burnat; Małgorzata Olszewska; Lidia Rudnicka
Journal:  Sci Rep       Date:  2021-01-11       Impact factor: 4.379

6.  CD123 immunoexpression in cutaneous lupus erythematosus, polymorphous light eruption, pityriasis rosea, and mycosis fungoides.

Authors:  Ebru Karagun; Mehmet Gamsizkan; Seyma Buyucek; Sinem Coskun
Journal:  Postepy Dermatol Alergol       Date:  2022-01-07       Impact factor: 1.837

7.  Mass Cytometric Analysis of Early-Stage Mycosis Fungoides.

Authors:  Nannan Guo; Li Jia; Coby Out-Luiting; Noel F C C de Miranda; Rein Willemze; Frits Koning; Maarten Vermeer; Koen Quint
Journal:  Cells       Date:  2022-03-22       Impact factor: 6.600

8.  Hypopigmented mycosis fungoides in type v skin: a report of 5 cases.

Authors:  Ranthilaka R Ranawaka; Priyanka H Abeygunasekara; M V Chandu de Silva
Journal:  Case Rep Dermatol Med       Date:  2011-12-20

9.  Defining the mimics and clinico-histological diagnosis criteria for mycosis fungoides to minimize misdiagnosis.

Authors:  A Kelati; S Gallouj; L Tahiri; T Harmouche; F Z Mernissi
Journal:  Int J Womens Dermatol       Date:  2017-01-30

10.  A Case of Cutaneous T-cell Lymphoma, Masquerading as Psoriasis, Was Given Etanercept and Secukinumab: Emphasizing the Need for Biopsy Confirmation before Starting Biologics.

Authors:  Abhishek De; Tanumay Raychaudhury; Murlidhar Rajagopalan; Aarti Sarda; Nidhi Sharma
Journal:  Indian J Dermatol       Date:  2017 Sep-Oct       Impact factor: 1.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.